Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Inclusion Criteria: * Body mass index 18.0 to 30.0 kg/m\^2, inclusive * Willing and able to participate in the whole study * Have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day) * Provide written informed consent * Adhere to the contraception requirements. Exclusion Criteria: * Have received any investigational medicine in a clinical research study within 90 days * Are, or are immediate family members of, a study site or sponsor employee * Evidence of current severe acute respiratory syndrome (SARS-CoV-2) infection * History of any drug or alcohol abuse, or regularly consume \>21 units alcohol per week * Current smoker or user of e-cigarettes and nicotine replacement products within the last 6 months * Have pregnant or lactating partners * Radiation exposure, exceeding 5 milliSieverts (mSv) in the last 12 months or 10 mSv in the last 5 years * Clinically significant abnormal results of clinical chemistry, hematology or urinalysis as judged by the investigator * Confirmed positive drugs of abuse test result * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results * Active renal and/or hepatic disease * History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder * Any form of cancer within the last 5 years (exceptions apply) * History and/or symptoms of adrenal insufficiency * Condition that could be aggravated by glucocorticoid antagonism or activation * Donation of blood or plasma or loss of greater than 400 mL of blood within the previous 3 months * Are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) within 14 days. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply on a case by case basis. * Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products * Additional criteria apply.